Immunity-inducing agent

Abstract

This application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from (a) polypeptides consisting of amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, (b) polypeptides having a sequence identity of 85% or more with the amino acid sequences represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 and 14, and polypeptides consisting of 7 or more consecutive amino acids in the amino acid sequences, and (c) polypeptides comprising the polypeptides according to (a) or (b) as the partial sequences, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo.

1 . An immunity-inducing agent comprising, as an active ingredient, (i) at least one polypeptide having immunity-inducing activity and selected from the following polypeptides (a), (b), and (c), or (ii) a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing said polypeptide in vivo:
 (a) a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence;   (b) a polypeptide having a sequence identity of 85% or more with the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14, and a polypeptide consisting of 7 or more consecutive amino acids in the amino acid sequence of the polypeptide;   (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence.   
     
     
         2 . The immunity-inducing agent according to  claim 1 , wherein the polypeptide having immunity-inducing activity is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8, 4, 6, 10, 12, 2 or 14. 
     
     
         3 . The immunity-inducing agent according to  claim 1 , which is for use in treating antigen-presenting cells. 
     
     
         4 . The immunity-inducing agent according to  claim 1 , which for use in treating and/or preventing a cancer. 
     
     
         5 . The immunity-inducing agent according to  claim 4 , wherein the cancer is a CSPG5 expressing cancer. 
     
     
         6 . The immunity-inducing agent according to  claim 4 , wherein the cancer is brain tumor, leukemia, malignant lymphoma, or neuroblastoma. 
     
     
         7 . The immunity-inducing agent according to  claim 1 , further comprising an immunoenhancer. 
     
     
         8 . The immunity-inducing agent according to  claim 7 , wherein the immunoenhancer is at least one selected from the group consisting of Freund's incomplete adjuvant, Montanide, Poly IC and derivatives thereof, CpG oligonucleotides, interleukin 12, interleukin 18, interferon α, interferon β, interferon ω, interferon γ, and Flt 3 ligand. 
     
     
         9 . A method for preparing an antigen-presenting cell containing a complex of the polypeptide defined in  claim 1  and an MHC molecule, comprising contacting the polypeptide with an antigen-presenting cell from a subject ex vivo or in vitro. 
     
     
         10 . The method according to  claim 9 , wherein the antigen-presenting cell is a dendritic cell or B cell having an MHC class I molecule. 
     
     
         11 . A method for preparing a cytotoxic T cell specific to the polypeptide defined in  claim 1 , comprising contacting the polypeptide with an antigen-presenting cell, and then contacting the antigen-presenting cell with a T cell from a subject ex vivo or in vitro, thereby activating the T cell. 
     
     
         12 . An antigen-presenting cell obtained by the method according to  claim 9  and containing a complex of the polypeptide and a MHC molecule. 
     
     
         13 . A cytotoxic T cell obtained by the method according to  claim 11  and specific to the polypeptide. 
     
     
         14 . The immunity-inducing agent according to  claim 2 , which is for use in treating antigen-presenting cells. 
     
     
         15 . The immunity-inducing agent according to  claim 2 , which for use in treating and/or preventing a cancer. 
     
     
         16 . The immunity-inducing agent according to  claim 5 , wherein the cancer is brain tumor, leukemia, malignant lymphoma, or neuroblastoma. 
     
     
         17 . The immunity-inducing agent according to  claim 2 , further comprising an immunoenhancer. 
     
     
         18 . The immunity-inducing agent according to  claim 3 , further comprising an immunoenhancer. 
     
     
         19 . The immunity-inducing agent according to  claim 4 , further comprising an immunoenhancer. 
     
     
         20 . The immunity-inducing agent according to  claim 5 , further comprising an immunoenhancer.